Instead of monotherapy with RXR agonists, the combination treatment of RXR and PPARγ agonists was shown to be more effective in increasing insulin sensitization and reducing hyperglycemia in murine models of obesity and non-insulin-dependent diabetes mellitus [37]. This evidence concerns the gene PPARG and diabetes mellitus.